SHINE and IOCB Prague enter Lu-177 process license agreement
Share

(Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague)) SHINE Medical Technologies, Inc. and IOCB Prague have entered into an intellectual property license agreement providing SHINE with a global, exclusive license to a novel method for separating rare earth elements. SHINE will use the innovation to produce lutetium-177 (Lu-177) for the treatment of cancer. The separation technique was developed by the team of Dr. Miloslav Polášek, from IOCB Prague.

read more...


Article originally posted at

www.eurekalert.org

Click here for the full story


Category
Tags

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD